The rationale for exploring endocrine therapy for the treatment of ovarian cancer patients is based on the high ER/PR expression as a predictive marker, since ovarian cancer is partly driven by the estrogen-pathway [27]. The gene discussed is ESR1; the disease is ovarian cancer.